

31st August, 2026

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release - Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release dated 31st August, 2026 on the captioned subject.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Simona Dsouza

Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)

This collaboration aims to accelerate development and future access to Rolditamig Deuderuxtecan for patients with breast cancer across India, South Africa and select emerging markets

Mumbai and Hong Kong, 31st August 2026: Cipla Limited (BSE: 500087; NSE: CIPLA) ("Cipla") and Sino Biopharmaceutical Limited (HKEX: 1177) ("SBP Group") today announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("CTTQ"), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate ("ADC").

Under this agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and 5 other emerging markets. Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.

TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer. The collaboration brings together SBP Group's differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla's established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets. The partnership is intended to accelerate local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals.

Commenting on the partnership, **Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla** said, "At Cipla, innovation is central to our mission of expanding access to therapies that address unmet patient needs. Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate. Through our partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access to this innovative treatment across licensed territories."

"Expanding global access to medicines developed by SBP Group is a central part of our strategy," said **Eric Tse, CEO, SBP Group**. "TQB2102 has demonstrated encouraging clinical potential across different HER2-expressing breast cancer populations. Cipla's scale, local expertise and commitment to patient access make it a strong partner to help bring this treatment to patients across India, South Africa and other emerging markets."

About Rolditamig Deuderuxtecan

Rolditamig Deuderuxtecan, also known as TQB2102, is a next-generation HER2 dual-epitope bispecific ADC independently developed by SBP Group. It simultaneously binds to the ECD II and ECD IV domains of HER2 and incorporates a cleavable linker and topoisomerase I inhibitor payload. The differentiated design is intended to overcome limitations associated with conventional HER2 monoclonal antibodies or single-target ADCs. In particular, the dual-epitope



binding mode may enhance receptor cross-linking and endocytosis efficiency, supporting potential differentiated advantages in the treatment of patients with HER2-low expression.

Rolditamig deuderuxtecan has received three Breakthrough Therapy Designations from the Center for Drug Evaluation of China's National Medical Products Administration. It is currently being evaluated for HER2-low, HER2-positive breast cancer, colorectal cancer, and biliary tract cancer across multiple treatment settings.

About SBP Group

Sino Biopharmaceutical Limited ("SBP Group," Stock Code: 1177.HK) is a leading, innovative R&D-driven pharmaceutical group in China, with fully integrated end-to-end capabilities spanning drug R&D, intelligent manufacturing, and commercial sales. The company holds a strong leadership position across oncology, liver, cardiometabolic, respiratory and autoimmune diseases.

SBP Group has established a leading oncology franchise in China with a broad portfolio spanning targeted therapies, immunotherapies, biologics, bispecifics, ADC and supportive care across multiple tumour types, including lung, breast, gastrointestinal, gynaecological, thyroid, renal and haematological cancers. Through its deep, innovation-led pipeline and development of differentiated combination regimens, the Group continues to advance standards of cancer care and expand patient access to innovative treatments. For more information, please visit <https://www.sbpgroup.com/>

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 48 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 69 markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Jun'26). For nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the center of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

investorrelations@cipla.com